Kestra Medical Technologies, Ltd., a commercial-stage wearable medical device and digital healthcare company, announced today the launch of its initial public offering (IPO) of 10 million common shares. The Kirkland, Washington-based company expects to price its shares between $14.00 and $16.00, potentially raising between $140 million and $160 million.
The company has also granted underwriters a 30-day option to purchase up to an additional 1.5 million common shares at the IPO price, less underwriting discounts and commissions. Kestra has applied to list its common shares on the Nasdaq Global Select Market under the ticker symbol "KMTS."
BofA Securities, Goldman Sachs, and Piper Sandler are serving as lead bookrunners for the offering, with Wells Fargo Securities and Stifel acting as additional bookrunners. Wolfe | Nomura Alliance is acting as co-manager for the proposed offering.
Cardiovascular Focus and Digital Health Innovation
Kestra specializes in developing wearable medical devices and digital healthcare solutions specifically designed to transform patient outcomes in cardiovascular disease. The company's approach integrates monitoring capabilities with therapeutic intervention technologies that are described as "intuitive, intelligent, and connected."
This IPO comes at a time when the digital health and wearable medical device market is experiencing significant growth, particularly for cardiovascular applications. Cardiovascular disease remains the leading cause of death globally, creating substantial demand for innovative monitoring and treatment solutions.
Market Position and Growth Potential
As a commercial-stage company, Kestra has already moved beyond the development phase to bringing products to market. The wearable medical device sector has seen increasing adoption among both healthcare providers and patients, particularly for chronic disease management.
The funds raised through this IPO will likely support Kestra's continued commercial expansion, research and development initiatives, and potential market penetration strategies. The company's focus on cardiovascular disease positions it in a large addressable market with significant unmet needs.
IPO Details and Regulatory Status
A registration statement relating to the offering has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The company notes that the securities may not be sold, nor may offers to buy be accepted, until the registration statement becomes effective.
Potential investors can obtain copies of the preliminary prospectus, when available, from the lead bookrunners. The offering will be made only by means of a prospectus, as required by securities regulations.
The IPO represents a significant milestone for Kestra as it transitions to public company status, potentially providing the capital needed to accelerate its growth in the competitive medical device and digital health landscape.
